Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation

Figures & data

Table 1. Patients’ pre-transplant clinical characteristics.

	P-ATG	Non-ATG	P-value
Number of patients	30	30
Gender			1.000
Male (%)	16 (53.3)	16 (53.3)
Female (%)	14 (46.7)	14 (46.7)
Age at treatment	47 (33–61)	35 (18–53)	<0.001
Years, median (range)
Diagnosis, n. of patients (%)			0.590
ALL	7 (23.3)	6 (20.0)
AML	16 (53.3)	13 (43.3)
MDS	6 (20.0)	7 (23.3)
Other	1 (3.3)	4 (13.3)
Pre-transplant remission, n. of patients (%)			0.209
CR	21 (70.0)	26 (86.7)
NR	9 (30.0)	4 (13.3)
Infection before HSCT, n. of patients (%)
Bacteremia	8 (26.7)	7 (23.3)	0.766
IFD	6 (20.0)	7 (23.3)	0.754
Viruses	4 (13.3)	2 (6.7)	0.671

Abbreviation: ATG, antithymocyte globulin; P-ATG, porcine ATG; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete remission; NR, no remission; HSCT, hematopoietic stem cell transplantation; IFD, invasive fungal disease.

Table 2. Treatment details.

	P-ATG	Non-ATG	P-value
Number of patients	30	30
Donor	MSD	MSD
Donor gender			0.195
Male (%)	16 (53.3)	11 (36.7)
Female (%)	14 (46.7)	19 (63.3)
Donor age	47 (34-58)	35 (17-58)	<0.001
Years, median (range)
Numbers of infusion PBSC MNC	11.1 (8.0-21.7)	10.1 (6.4-27.7)	0.490
median (range) × 10^8/kg CD34^+ cells median (range) × 10^6/kg	2.4 (1.4-4.6)	2.5 (1.7, 5.7)	0.375

Abbreviations: ATG, anti-thymocyte globulin; P-ATG, porcine ATG; MSD, HLA-matched siblings; PBSC, peripheral blood stem cell; MNC, mononuclear cells.

Figure 1. Incidence of GVHD in the two groups (a) aGVHD. (b) III–IV aGVHD. (c) cGVHD. (d) moderate-severe cGVHD.

Figure 2. Comparison of 1-year survival rate of the two groups’ patients.

Table 3. The outcomes of the two groups’ patients.

	P-ATG	Non-ATG	P-value
Number of patients	30	30
Engraftment
ANC, Days, median (range)	12 (9–16)	12 (11–20)	0.530
PLT, Days, median (range)	15 (8–38)	13 (10–23)	0.127
GVHD
aGVHD (%)	23.3 (10.1–39.7)	50.0 (30.8–66.5)	0.028
Grade II–IV aGVHD (%)	16.7 (5.94–32.1)	40.0 (22.4–57.0)	0.049
cGVHD (%)	22.4 (6.03–45.1)	69.0 (43.4–84.8)	0.001
Moderate–severe cGVHD (%)	12.5 (1.67–34.8)	25.9 (9.82–45.6)	0.129
RR (%)	13.6 (2.73–33.2)	15.2 (4.40–32.1)	0.742
NRM (%)	16.7 (5.95–32.1)	6.67 (1.14–19.5)	0.237
OS (%)	79.9 (60.5–90.4)	84.0 (61.2–94.0)	0.441
Infection
n. of patients (%)	6 (20.0)	3 (10.0)	0.472
Severe Bacterial infection	7 (23.3)	6 (20.0)	1.000
IFD	7(23.3)	4 (13.3)	0.298
CMV infection

Abbreviations: ATG, anti-thymocyte globulin; P-ATG, porcine ATG; ANC, Neutrophil; PLT, platelet; GVHD, graft versus host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; RR, relapse rate; NRM, non-relapse mortality; DFS, disease-free survival; OS, overall survival; IFD, invasive fungal disease; CMV, cytomegalovirus.

Data availability statement

Data are available on request from the authors.